MGMaksim Vasil'EVich Gorbunov

Maksim Vasil'EVich Gorbunov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Maksim Vasil'EVich Gorbunov has a total of 7 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Prognostic value of cystatin С in pulmonary embolism

    by M. V. Menzorov, V. V. Matyushina, A. M. Shutov, M. V. Gorbunov, V. M. Menzorov

    BACKGROUND. Standard criteria allow diagnosing AKI within hours to days. The use of biomarkers is a promising approach for early diagnosis and prognosis of AKI. THE AIM: to study the capabilities of serum cystatin C (CYS) in the early diagnosis and prognosis of AKI and associated hospital mortality, the risk of 30-day death in pulmonary embolism (PE). PATIENTS (MATERILS) AND METHODS. 98 patients with suspected PE were included; patients were excluded if the diagnosis was not confirmed. CYS was determined on admission, the difference between the determined CYS and the estimated CYS corresponding to a glomerular filtration rate (GFR) of 75 ml/min/1.73 m2 (CYSdiff) and the difference between the GFR by CYS and the GFR by creatinine (eGFRdiff) were calculated. RESULTS. AKI was diagnosed in 13 of 63 patients with PE (men – 36(57 %), age – 67(12) years). In 7(54 %) cases, AKI was detected against the background of chronic kidney disease (CKD), in 6(46 %) – first-onset AKI. CYS>2.55 μg/ ml predicted AKI (sensitivity – 70 %, specificity – 62 %; AUC=0,70; p=0,01) and AKI in CKD patients (sensitivity – 86 %, specificity – 62 %; AUC=0,78; p=0,001). CYSdiff>1,62 μg/ml predicted AKI (sensitivity – 69 %, specificity – 68 %; AUC=0,70; p=0,01). 5 patients (9 %) died in hospital. Mortality was higher in AKI (χ2 =5.8; p=0,02). CYS, CYSdiff did not predict hospital mortality, while CYS>2,17 μg/ml (sensitivity – 70 %, specificity – 70 %; AUC=0,76; p=0,0001) and CYSdiff>1,22 μg/ml (sensitivity – 70 %, specificity – 70 %; AUC=0.77; p0,05). CONCLUSION. The results of the study confirm the effectiveness of CYS in the early diagnosis and prediction of AKI, including cases associated with CKD. The accuracy of prediction can be improved using CYSdiff. CYS does not predict in-hospital mortality but is associated with a high risk of 30-day death in PE.

  • Open Access

    Prognostic Value of Cystatin C in Pulmonary Embolism

    by M. V. Menzorov, V. V. Matyushina, A. M. Shutov, M. V. Gorbunov, V. M. Menzorov

    Aim To study a possibility of using serum concentrations of cystatin C (CYS) in early diagnosis and prediction of acute kidney injury (AKI) and associated in-hospital mortality and 30-day risk of death in pulmonary embolism (PE). Materials and methods This study included 98 patients with suspected PE, of whom 63 had a confirmed diagnosis and formed the study group; the rest were excluded. CYS was measured on admission. The difference (CYSdiff) between the measured CYS and the estimated CYS corresponding to the glomerular filtration rate (GFR) of 75 ml/min/1.73 m 2 was calculated using the reversed 2012 CKD-EPI Cystatin C formula. The estimated GFR was calculated as the difference between the CYS-based GFR (2012 CKD-EPI Cystatin C) and the creatinine-based GFR (2009 CKD-EPI). The 30-day mortality risk was assessed according to the ESC/ERS Guidelines for the diagnosis and treatment of acute PE in effect at the time of hospitalization. Results AKI was diagnosed in 13 (21%) of 63 patients with PE aged 67±12 years, of whom 36 (57%) were men. In 7 (54%) cases, AKI was associated with chronic kidney disease (CKD), and in 6 (46%) cases, AKI developed for the first time. The measurement of the CYS concentration ensured early diagnosis and prediction of AKI with AUC=0.70 (95% confidence interval (CI) 0.57-0.81; p =0.009), optimal cutoff point (OP) >2.55 μg/ml (sensitivity 70%, specificity 62%), and AKI associated with CKD with AUC=0.78 (95% CI 0.65-0.88; p =0.001), OP >2.55 μg/ml (sensitivity 86%, specificity 62%). Similar predictive value for AKI was determined for CYSdiff: AUC = 0.70 (95% CI 0.57-0.81; p =0.009), OP >1.62 μg/ml with a sensitivity of 69% and specificity of 68%. Five patients (9%) died in hospital. The death rate was higher in AKI (χ2 = 5.8; p =0.018). CYS and CYSdiff levels did not predict in-hospital mortality (p >0.05 for both). The predictive value of eGFRdiff was unsatisfactory for either AKI or mortality ( p >0.05 for both). It was found that CYS (AUC=0.76; 95% CI 0.63-0.85; p 2.17 μg/ml) with a sensitivity of 70%, specificity of 70%, and CYSdiff (AUC=0.77; 95% CI 0.64–0.86; p1.22 μg/ml) with a sensitivity of 70%, and specificity of 70%, but not eGFRdiff were associated with a high 30-day risk of death ( p =0.804). Conclusion The study results confirm the effectiveness of CYS assessment in the early diagnosis and prediction of AKI, including cases associated with CKD. Prediction accuracy can be improved using CYSdiff. CYS levels do not predict in-hospital mortality but are associated with a high 30-day risk of death in patients with PE.

  • ACUTE KIDNEY INJURY IN PATIENTS WITH MYOCARDIAL INFARCTION AND NEW CORONAVIRUS INFECTION (COVID-19)

    by Anna Yur'EVna Denisova, Maksim Vital'EVich Menzorov, Sabina Faigovna Kerimova, Maksim Vasil'EVich Gorbunov, Viktor Maksimovich Menzorov, Emma Olegovna Bubas

    Acute kidney injury is a common pathological condition that complicates various diseases and affects both the short-term and long-term prognosis. There is ample research which testifies the unfavorable prognostic role of acute kidney injury in patients with myocardial infarction. The problem of acute kidney injury has become especially relevant during the COVID-19 pandemic, periodic outbreaks of which associated with new virus mutation are still observed. COVID-19 can both destabilize the existing pathology and lead to the development of new diseases, including myocardial infarction. In patients with myocardial infarction and COVID-19, a multiplicative risk effect of getting acute kidney injury is expected, the mechanism of which is likely to be different in each particular case: COVID-19 can simultaneously lead to a combination of renal and cardiac complications; acute kidney injury can develop due to heart failure, direct heart injury or myocardial infarction regardless of the new coronavirus infection. The article reviews the studies on the correlation between creatinine levels, renal dysfunction and the risk of myocardial infarction in COVID-19 patients. The authors describe the pathophysiological basis of cardiorenal correlation in COVID-19, which is characterized by the complexity and uniqueness of changes.